Cigarette smoking remains one of the most persistent and preventable causes of disease worldwide, exposing people to a complex mixture of toxic substances produced when tobacco burns. A forthcoming article in JAMA argues that the scale of this harm, together with scientific evidence that e-cigarettes can help some adults stop smoking, makes it appropriate to include e-cigarettes in clinical discussions about evidence-based pharmacologic treatment for smoking cessation. The recommendations are designed to help clinicians address vaping as part of a structured strategy to reduce the health risks associated with combustible cigarettes.
The central scientific distinction is combustion. Conventional cigarettes burn tobacco at high temperatures, generating smoke containing thousands of chemical compounds, including carbon monoxide, fine particulate matter, and numerous carcinogens. E-cigarettes do not burn tobacco. Instead, an electrically heated element vaporizes a liquid that commonly contains nicotine, solvents such as propylene glycol and vegetable glycerin, and flavoring chemicals. The resulting aerosol is not harmless, but its chemical composition and toxicant profile differ substantially from those of cigarette smoke. This difference forms the foundation of the harm-reduction argument surrounding adult smokers who cannot or do not want to quit nicotine immediately.
The article’s recommendations are expected to focus on clinical decision-making rather than presenting e-cigarettes as risk-free consumer products. Nicotine is highly addictive and can affect cardiovascular function, while inhaled aerosol may contain irritants, ultrafine particles, metals released from device components, and other substances whose long-term effects continue to be studied. Device design, liquid formulation, heating temperature, and user behavior can all influence exposure. For that reason, a clinician’s role is not simply to recommend or reject vaping, but to assess the individual’s smoking history, previous quit attempts, dependence, medical conditions, and likelihood of switching completely away from combustible tobacco.
Evidence supporting e-cigarettes for cessation has generally examined whether smokers are more likely to stop using cigarettes when given access to vaping products, often alongside behavioral support. In this context, the relevant clinical outcome is not whether a person becomes nicotine-free immediately, but whether they discontinue cigarette smoking and maintain abstinence over time. The recommendations emphasize that a complete transition away from combustible cigarettes is critical. Continuing to smoke while also vaping, a pattern known as dual use, may limit potential health benefits because exposure to cigarette smoke persists.
Pharmacologic treatment for smoking cessation traditionally includes nicotine replacement therapy, varenicline, and bupropion, depending on a patient’s health profile and preferences. These therapies work through different mechanisms. Nicotine patches, gum, lozenges, inhalers, and nasal sprays provide controlled nicotine doses without tobacco combustion. Varenicline partially stimulates nicotine receptors in the brain while reducing the rewarding effects of smoking, and bupropion alters neurotransmitter activity associated with craving and withdrawal. E-cigarettes also deliver nicotine, but they can reproduce behavioral and sensory elements of smoking, including hand-to-mouth movement and inhalation, which may help some smokers manage conditioned habits.
The clinical guidance is therefore likely to treat e-cigarettes as one possible cessation tool within shared decision-making. A patient who has repeatedly failed to quit with approved medications, or who strongly prefers an inhaled nicotine product, may benefit from a carefully monitored attempt to switch completely from cigarettes to e-cigarettes. Clinicians may need to explain nicotine concentrations, product variability, dependence risks, and the importance of setting a plan to reduce or eventually stop vaping. Counseling should also distinguish adult smoking cessation from youth prevention, because nicotine exposure is particularly concerning for adolescents, pregnant people, and individuals who do not already smoke.
The recommendations arrive amid continuing scientific debate over how to communicate the relative risks of vaping. Public health messages must navigate two hazards at once: overstating the dangers of e-cigarettes may discourage smokers from switching, while understating them may encourage non-smokers, especially young people, to begin using nicotine. Relative-risk communication is technically difficult because the comparison is not between vaping and clean air alone. For an adult who otherwise would continue smoking, replacing cigarettes with regulated nicotine aerosol may reduce exposure to combustion-related toxicants. For a non-smoker, beginning to vape introduces avoidable exposure and the possibility of addiction.
Leavens and colleagues also highlight the need for clinicians to discuss evidence quality and uncertainty. Research on cessation outcomes has produced meaningful support for e-cigarettes, but products differ widely and long-term epidemiologic data remain less extensive than the evidence base for cigarette-related disease. Outcomes can be affected by product access, nicotine delivery, adherence, counseling intensity, and whether participants use e-cigarettes exclusively or alongside cigarettes. A scientifically responsible recommendation must therefore separate established findings from unresolved questions, monitor emerging safety data, and avoid treating all vaping products as biologically identical.
For patients, the practical message is that quitting cigarettes remains the primary goal, and evidence-based support should be individualized. People who choose e-cigarettes as a cessation aid should be encouraged to stop smoking completely, receive behavioral counseling, and maintain follow-up with a health professional. Clinicians can reassess cravings, withdrawal symptoms, nicotine intake, respiratory complaints, and progress toward cigarette abstinence. If vaping does not help a patient quit, other medications or combinations of treatments may be appropriate. The broader objective is to move people away from the most dangerous form of nicotine use: inhaling smoke produced by burning tobacco.
By placing e-cigarettes within the broader framework of smoking-cessation pharmacology, the JAMA article seeks to bring clinical practice into closer alignment with the evidence surrounding nicotine delivery and tobacco-related harm. Its approach does not eliminate the controversies surrounding vaping, nor does it declare electronic devices safe. Instead, it recognizes a harm-reduction reality: for adults who smoke, the health consequences of continued combustion exposure are severe, and some may be more likely to quit cigarettes with an e-cigarette than with other available options. The challenge for medicine is to use that potential strategically while preventing new nicotine addiction and ensuring that complete cigarette cessation remains the destination.
Subject of Research: Clinical recommendations on the use of e-cigarettes as a smoking-cessation intervention and their role in evidence-based pharmacologic treatment.
Web References: https://doi.org/10.1001/jama.2026.13087
References: Leavens, Eleanor L. S., et al. Article published in JAMA. DOI: 10.1001/jama.2026.13087.
Keywords: E-cigarettes, electronic cigarettes, smoking cessation, nicotine, tobacco harm reduction, pharmacologic treatment, cigarette smoking, clinical guidance, aerosol exposure, dual use, combustion products, public health
Tags: chemical composition of e-cigarette aerosolsclinical guidelines for vaping as a cessation tooldifferences between cigarette smoke and e-cigarette vapore-cigarette health risksevidence-based pharmacologic treatments for tobacco addictionharm reduction strategies for adult smokershealth impacts of vaping versus smokingpublic health implications of e-cigarette userole of nicotine in smoking cessationsmoking cessationstrategies to reduce smoking-related diseasestobacco combustion and toxicant production
